AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Chemotherapeutic Toxicity
Interventions: DRUG: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University